David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Sébastien Maury, MD, on ALL: Results of the Graall-R 2005 Study (French Language Version)

Sébastien Maury, MD, of the Hôpital Henri Mondor, discusses in French this study in which adding rituximab improved the outcome of adult patients with CD20-positive, Ph-negative B-cell precursor acute lymphoblastic leukemia (Abstract 1).

Multiple Myeloma

Sagar Lonial, MD, and Torben Plesner, MD

Sagar Lonial, MD, and Torben Plesner, MD, on Multiple Myeloma: Updated Results of the Phase I/II GEN503 Study

Sagar Lonial, MD, of Emory University School of Medicine, and Torben Plesner, MD, of Vejle Hospital, discuss the latest findings on the use of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (Abstract 507).

Leukemia

James Foran, MD

James Foran, MD, on Clofarabine for AML: Clinical Trial Results of ECOG-ACRIN and ALFA/Clara

James Foran, MD, of the Mayo Clinic Cancer Center, discusses two key studies on clofarabine: as a single agent for induction and postremission therapy in newly diagnosed AML, and as the basis for consolidation in nonfavorable AML (Abstracts 217 and 218).

Lymphoma

Simon Rule, MD

Simon Rule, MD, on MCL: Ibrutinib vs Temsirolimus

Simon Rule, MD, of Derriford Hospital, discusses results from an international, multicenter study in patients with previously treated mantle cell lymphoma (Abstract 469).

Lymphoma

Laurie H. Sehn, MD, MPH

Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy

Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a study that showed patients with advanced-stage classical Hodgkin lymphoma, with a negative PET-scan following ABVD chemotherapy, have excellent outcomes without the need for consolidative radiotherapy, regardless of disease bulk at presentation (Abstract 579).

Jun

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Sébastien Maury, MD, on ALL: Results of the Graall-R 2005 Study (French Language Version)

Sagar Lonial, MD, and Torben Plesner, MD, on Multiple Myeloma: Updated Results of the Phase I/II GEN503 Study

James Foran, MD, on Clofarabine for AML: Clinical Trial Results of ECOG-ACRIN and ALFA/Clara

Simon Rule, MD, on MCL: Ibrutinib vs Temsirolimus

Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy

FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer

AGA Recommends Colonoscopy Over Alternative Colorectal Cancer Screening Methods

AI-Assisted Tumor Volume Response Criteria Outperform Physician Assessments and RECIST Criteria in Pleural Mesothelioma

Overall Survival With EBRT in Hepatocellular Carcinoma

HCC TACE Plus STRIDE With or Without Lenvatinib